arrow
L

Luca Prosperini

san camillo-forlanini hospital
H指数:53
被引数:7,704

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis

从边缘到中心:边缘区样B细胞作为克拉屈滨治疗多发性硬化的关键靶点

2026-06-180
OAAI
Rethinking prognosis in multiple sclerosis: a multiaxial perspective

重新思考多发性硬化的预后:一种多轴视角

2026-05-190
PRE
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study

真实世界中多发性硬化患者使用克拉屈滨片的经验:一项多中心意大利研究的有效性数据

2025-12-260
OA
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies

多发性硬化患者在接受疾病修饰疗法时,对COVID-19疫苗的Th1特异性反应与SARS-CoV-2突破性感染之间关联性极低。

2025-10-300
OAAI
Epilepsy in MS and its association with cognitive and psychological burden

多发性硬化中的癫痫及其与认知和心理负担的关联

2025-07-310
OA
Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination
2024-08-190
OAAI
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
2024-07-170
OAAI
An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study

基于互联网和Kinect的多发性硬化症健身干预训练与普拉提练习: 开发和可用性研究

2023-11-081
OAAI
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

在现实环境中评估口服药物对多发性硬化症的治疗反应: 一项MAGNIMS研究

2023-09-296
PRE
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

用高效dmt治疗的多发性硬化症患者接受三种mRNA疫苗剂量后的症状性新型冠状病毒肺炎过程和结局

2023-05-117
OA
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
2022-12-1516
OAAI